Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
WAT Stock Summary
Top 10 Correlated ETFs
WAT
In the News

Waters Corporation to Present at the Evercore ISI HealthCONx 2023 Health Care Conference
MILFORD, Mass. , Nov. 16, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D.

Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
Waters' (WAT) Q3 results benefit from a strong Pharmaceutical market, as well as a strong contribution from the Wyatt acquisition.

Waters Corporation (WAT) Q3 2023 Earnings Call Transcript
Waters Corporation (NYSE:WAT ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Caspar Tudor – Head-Investor Relations Udit Batra – President and Chief Executive Officer Amol Chaubal – Senior Vice President and Chief Financial Officer Conference Call Participants Vijay Kumar – Evercore ISI Dan Brennan – TD Cowen Matt Sykes – Goldman Sachs Derik De Bruin – Bank of America Rachel Vatnsdal – JPMorgan Eve Burstein – Bernstein Research Operator Good morning. Welcome to the Waters Corporation Third Quarter 2023 Financial Results Conference Call.

Curious about Waters (WAT) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Waters (WAT) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Waters (WAT) to Report Q3 Earnings: What's in the Offing?
Waters' (WAT) third-quarter 2023 results are likely to reflect strength in liquid chromatography instruments and mass spectrometers amid uncertainties in the global economy.

Among the S&P 500, these 20 companies have made the best use of investors' money
There is no easy way to select individual stocks. Measures of financial quality can highlight companies that are worth a closer look, but a decision to commit money must also take into consideration both recent developments and a look ahead.

Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move
Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.

Waters Corporation: Buybacks Ceased, Incremental Returns Languishing (Rating Downgrade)
Waters Corporation has pushed lower into H2 FY'23, in continuation of the longer-term downtrend. WAT's acquisition of Wyatt Technology was a large premium that to me signaled a lack of profitable investment runway. Despite exceptional returns on existing capital, the incremental returns don't match these numbers, clamping earnings and FCF growth.

Waters Has Made Progress In Repositioning The Business, And The Valuation Is Much More Accommodating Now
Waters Corporation has seen a significant hit to its share price as momentum has left the life sciences tools space and as spending from the key biopharma end-market has corrected. Biopharma spending likely won't return to the torrid pace of the boom years, but ongoing investments into discovery tools, production equipment, and QA/QC equipment should drive healthy growth. The company's presence in industrial markets, such as food and water quality testing, provides a steady source of profitability and growth potential in areas like battery testing and sustainable polymers.

Waters Corporation (WAT) Bank of America Global Healthcare Conference 2023 (Transcript)
Waters Corporation (NYSE:WAT ) Bank of America Global Healthcare Conference 2023 Call September 13, 2023 8:20 AM ET Company Participants Udit Batra - President and Chief Executive Officer Conference Call Participants Derik De Bruin - Bank of America Merrill Lynch Derik De Bruin Good afternoon, and welcome to Bank of America's Global Healthcare Conference Community Live from London. I'm Derik De Bruin, the Senior U.S. Life Sciences and Diagnostics Tools analyst, and it is my pleasure to welcome our next company, which is Waters Corp. Today with me, we have Dr. Udit Batra, President and CEO of Waters.
WAT Financial details
WAT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 31.43 | 35.59 | 38.09 | 45.24 | 49.54 | |
Net income per share | 7.71 | 8.76 | 8.4 | 11.25 | 11.8 | |
Operating cash flow per share | 7.85 | 9.51 | 12.73 | 12.14 | 10.2 | |
Free cash flow per share | 6.19 | 7.09 | 9.95 | 9.4 | 7.14 | |
Cash per share | 22.54 | 4.99 | 7.14 | 9.25 | 8.03 | |
Book value per share | 20.36 | -3.2 | 3.74 | 5.97 | 8.41 | |
Tangible book value per share | 12.53 | -12.02 | -7.58 | -5.08 | -2.55 | |
Share holders equity per share | 20.36 | -3.2 | 3.74 | 5.97 | 8.41 | |
Interest debt per share | 29.96 | 49.62 | 25.24 | 25.57 | 28.16 | |
Market cap | 14.52B | 15.8B | 15.36B | 22.94B | 20.55B | |
Enterprise value | 16.02B | 17.15B | 16.28B | 23.96B | 21.72B | |
P/E ratio | 24.46 | 26.68 | 29.46 | 33.11 | 29.03 | |
Price to sales ratio | 6 | 6.57 | 6.5 | 8.24 | 6.91 | |
POCF ratio | 24.03 | 24.57 | 19.43 | 30.7 | 33.6 | |
PFCF ratio | 30.46 | 32.97 | 24.85 | 39.62 | 47.99 | |
P/B Ratio | 9.27 | -73.06 | 66.18 | 62.42 | 40.73 | |
PTB ratio | 9.27 | -73.06 | 66.18 | 62.42 | 40.73 | |
EV to sales | 6.62 | 7.12 | 6.88 | 8.6 | 7.31 | |
Enterprise value over EBITDA | 20.03 | 21.16 | 20.69 | 24.55 | 21.38 | |
EV to operating cash flow | 26.51 | 26.66 | 20.6 | 32.06 | 35.51 | |
EV to free cash flow | 33.6 | 35.78 | 26.34 | 41.37 | 50.72 | |
Earnings yield | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | |
Free cash flow yield | 0.03 | 0.03 | 0.04 | 0.03 | 0.02 | |
Debt to equity | 1.47 | -15.39 | 6.61 | 4.19 | 3.27 | |
Debt to assets | 0.62 | 1.3 | 0.54 | 0.5 | 0.5 | |
Net debt to EBITDA | 1.88 | 1.66 | 1.17 | 1.04 | 1.15 | |
Current ratio | 2.26 | 0.74 | 1.64 | 2.26 | 2.11 | |
Interest coverage | 75.23 | 26.6 | 19.68 | 25.12 | 23.12 | |
Income quality | 1.02 | 1.09 | 1.52 | 1.08 | 0.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | |
Intangibles to total assets | 0.16 | 0.23 | 0.25 | 0.22 | 0.2 | |
Capex to operating cash flow | -0.21 | -0.25 | -0.22 | -0.23 | -0.3 | |
Capex to revenue | -0.05 | -0.07 | -0.07 | -0.06 | -0.06 | |
Capex to depreciation | -1.18 | -1.56 | -1.27 | -1.28 | -1.41 | |
Stock based compensation to revenue | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
Graham number | 59.43 | 25.1 | 26.58 | 38.87 | 47.25 | |
ROIC | 0.17 | 0.19 | 0.3 | 0.35 | 0.33 | |
Return on tangible assets | 0.19 | 0.3 | 0.24 | 0.29 | 0.27 | |
Graham Net | 1.91 | -27.14 | -25.49 | -24.69 | -25.43 | |
Working capital | 1.45B | -435.73M | 515.76M | 857.52M | 874.26M | |
Tangible asset value | 964.74M | -812.61M | -470.86M | -312.71M | -153.24M | |
Net current asset value | 434.94M | -1.53B | -1.29B | -1.19B | -1.12B | |
Invested capital | 1.47 | -15.39 | 6.61 | 4.19 | 3.27 | |
Average receivables | 551.07M | 578.03M | 580.53M | 592.98M | 667.77M | |
Average payables | 66.35M | 58.58M | 60.61M | 84.51M | 95.05M | |
Average inventory | 280.93M | 306.06M | 312.42M | 330.19M | 405.9M | |
Days sales outstanding | 85.72 | 89.14 | 88.47 | 80.27 | 88.78 | |
Days payables outstanding | 25.07 | 17.7 | 26.18 | 30.55 | 27.28 | |
Days of inventory on hand | 107.22 | 115.76 | 110.32 | 112.38 | 133.26 | |
Receivables turnover | 4.26 | 4.09 | 4.13 | 4.55 | 4.11 | |
Payables turnover | 14.56 | 20.63 | 13.94 | 11.95 | 13.38 | |
Inventory turnover | 3.4 | 3.15 | 3.31 | 3.25 | 2.74 | |
ROE | 0.38 | -2.74 | 2.25 | 1.89 | 1.4 | |
Capex per share | -1.66 | -2.42 | -2.78 | -2.73 | -3.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-10-01 | 2022-12-31 | 2023-04-01 | 2023-07-01 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 11.85 | 14.47 | 11.6 | 12.58 | 12.04 | |
Net income per share | 2.61 | 3.83 | 2.39 | 2.56 | 2.28 | |
Operating cash flow per share | 2.64 | 3.35 | 3.33 | 0.31 | 2.67 | |
Free cash flow per share | 1.95 | 2.3 | 2.75 | -0.48 | 2.03 | |
Cash per share | 7.43 | 8.11 | 8.25 | 5.62 | 5.71 | |
Book value per share | 6.44 | 8.5 | 10.16 | 13.1 | 15.32 | |
Tangible book value per share | -4.15 | -2.58 | -1.09 | -20.25 | -17.49 | |
Share holders equity per share | 6.44 | 8.5 | 10.16 | 13.1 | 15.32 | |
Interest debt per share | 27.23 | 28.01 | 50.54 | 46.66 | 85.41 | |
Market cap | 16.12B | 20.32B | 18.28B | 15.69B | 16.2B | |
Enterprise value | 17.29B | 21.5B | 19.27B | 18.08B | 18.37B | |
P/E ratio | 25.83 | 22.38 | 32.42 | 26.05 | 30.11 | |
Price to sales ratio | 22.75 | 23.67 | 26.69 | 21.18 | 22.77 | |
POCF ratio | 101.96 | 102.28 | 92.89 | 865.87 | 102.67 | |
PFCF ratio | 138.4 | 148.87 | 112.56 | -550.66 | 135.29 | |
P/B Ratio | 41.84 | 40.29 | 30.47 | 20.34 | 17.89 | |
PTB ratio | 41.84 | 40.29 | 30.47 | 20.34 | 17.89 | |
EV to sales | 24.41 | 25.04 | 28.14 | 24.41 | 25.82 | |
Enterprise value over EBITDA | 76.82 | 67.76 | 93.22 | 74.58 | 80.74 | |
EV to operating cash flow | 109.39 | 108.18 | 97.94 | 997.96 | 116.42 | |
EV to free cash flow | 148.49 | 157.45 | 118.68 | -634.67 | 153.4 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
Debt to equity | 4.2 | 3.27 | 4.96 | 3.53 | 5.54 | |
Debt to assets | 0.53 | 0.5 | 0.9 | 0.6 | 1.12 | |
Net debt to EBITDA | 5.22 | 3.69 | 4.81 | 9.87 | 9.53 | |
Current ratio | 2.03 | 2.11 | 1.13 | 2.08 | 0.6 | |
Interest coverage | 20.16 | 27.49 | 16.77 | 8.59 | 6.76 | |
Income quality | 1.01 | 0.88 | 1.4 | 0.12 | 1.17 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | |
Intangibles to total assets | 0.21 | 0.2 | 0.2 | 0.43 | 0.43 | |
Capex to operating cash flow | -0.26 | -0.31 | -0.17 | -2.57 | -0.24 | |
Capex to revenue | -0.06 | -0.07 | -0.05 | -0.06 | -0.05 | |
Capex to depreciation | -1.29 | -1.99 | -1.1 | -1.2 | -0.8 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
Graham number | 19.44 | 27.06 | 23.37 | 27.46 | 28.02 | |
ROIC | 0.08 | 0.11 | 0.04 | 0.05 | 0.03 | |
Return on tangible assets | 0.06 | 0.09 | 0.05 | 0.06 | 0.05 | |
Graham Net | -26.23 | -25.71 | -24.7 | -45.16 | -42.45 | |
Working capital | 755.7M | 874.26M | 189.55M | 871.8M | -992.27M | |
Tangible asset value | -248.45M | -153.24M | -64.53M | -1.19B | -1.03B | |
Net current asset value | -1.2B | -1.12B | -1.04B | -2.1B | -2.08B | |
Invested capital | 4.2 | 3.27 | 4.96 | 3.53 | 5.54 | |
Average receivables | 620.19M | 661.91M | 703.12M | 688.39M | 662.36M | |
Average payables | 97.27M | 94.93M | 93.43M | 87.74M | 80.88M | |
Average inventory | 426.08M | 448.97M | 477.57M | 518.13M | 540.62M | |
Days sales outstanding | 76.33 | 75.78 | 89.82 | 84.27 | 79.83 | |
Days payables outstanding | 28.3 | 24.12 | 29.61 | 24.49 | 24.66 | |
Days of inventory on hand | 129.6 | 117.79 | 158.06 | 160.47 | 168.14 | |
Receivables turnover | 1.18 | 1.19 | 1 | 1.07 | 1.13 | |
Payables turnover | 3.18 | 3.73 | 3.04 | 3.68 | 3.65 | |
Inventory turnover | 0.69 | 0.76 | 0.57 | 0.56 | 0.54 | |
ROE | 0.4 | 0.45 | 0.23 | 0.2 | 0.15 | |
Capex per share | -0.7 | -1.05 | -0.58 | -0.79 | -0.64 |
WAT Frequently Asked Questions
What is Waters Corporation stock symbol ?
Waters Corporation is a US stock , located in Milford of Ma and trading under the symbol WAT
Is Waters Corporation buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $340. The lowest prediction is $315 and the highest is $365
What is WAT stock prediction ?
What is Waters Corporation stock quote today ?
Waters Corporation stock price is $275.95 today.
Is Waters Corporation stock public?
Yes, Waters Corporation is a publicly traded company.